3[1]Ranaboldo CJ, Mitchel A, Royal GT, et al. Axillary nodal status in women with screen-detected breast cancer. Eur J Surg Oncol, 1993, 19:130
4[2]Valagussa P, Bonadonna G, Veronesi V. Patterns of relapse and survival following radical mastectomy. Cancer, 1978, 41:1170
5[3]Voordeckers M, Vinh HV, Van S. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol, 2004, 70:225
6[4]Weiss RB, Woolf SH, Demako E, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracialbased adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. J Clin Oncol, 2003, 21:1825
7[5]Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet, 1998, 352:930
8[6]Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women. Lancet,1992, 339:1
9[7]Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow up. N Engl J Med, 1995, 332:901
10[8]Henderson IC, berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003,21: 976
